Core Insights - Zai Lab is advancing its global oncology pipeline with a focus on zoci, a DLL3-targeting antibody-drug conjugate, which is in a global registrational Phase III study for small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs) [2][6][3] - The company anticipates an accelerated approval submission for zoci in 2027 and a first global approval in 2028, with promising clinical activity demonstrated in patients with brain metastases [1][6][3] - Zai Lab's commercially profitable business in China is funding its global R&D efforts, with fourth-quarter revenue increasing by 17% year-over-year to $127.6 million and a full-year revenue of $460 million [5][14] Pipeline Development - Zai Lab has initiated a global registrational Phase III study for zoci, targeting approximately 480 patients, with enrollment expected to reach 75% by the end of 2026 [2][6] - Additional pipeline developments include ZL-6201, which has received U.S. IND clearance and is entering a global Phase I study, and ZL-1222, which is progressing through IND-enabling studies [4][8] - The company is also advancing ZL-1503 for atopic dermatitis and plans to present initial data for NECs in the first half of 2026 [9][10] Financial Performance - Zai Lab reported a 19% improvement in operating loss to $229.4 million for the full year, with cash reserves of $790 million as it aims for corporate cash-flow breakeven [5][21] - R&D expenses decreased by 6% year-over-year, while SG&A expenses also saw a reduction, contributing to improved financial leverage [20][21] - The company expects a more measured growth profile in 2026, influenced by pricing dynamics and competition, while maintaining a long-term growth trajectory supported by guideline expansions [15][22] Strategic Focus - Zai Lab is focusing on building a globally innovative company, leveraging its China business for stability and funding [3] - The company is exploring first-line SCLC combination strategies and strengthening its oncology platform through targeted collaborations [13] - Zai Lab plans to initiate the commercial launch of KarXT in the second quarter of 2026, emphasizing disease awareness and clinical confidence [17]

I think that um right now we are at a decisionmaking point and very close to a recession and I'm worried about something worse than a recession if this isn't handled well. A recession is two negative quarters of GDP and whether it goes slightly there. We always have those things. We have something that's much more profound. We have a breaking down of the monetary order. we are going to change the monetary order because we cannot spend the amounts of money. So we have that problem and when we talk about the ...